Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024040 | 0.89 | ALDH1A1 (0.40) | ALDH1A1TDP1CYP2C9TSHRMGAM | |
| SCHEMBL8319170 | 0.89 | ALDH1A1 (0.40) | ALDH1A1TDP1CYP2C9TSHRMGAM | |
| SCHEMBL10024038 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TDP1CYP2C9TSHR | |
| SCHEMBL10024033 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TDP1CYP2C9TSHR | |
| SCHEMBL10915894 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL4059136 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL1772274 | 0.78 | — | — | |
| SCHEMBL7668396 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL10024039 | 0.73 | MGAM (0.38) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL10110046 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148550-B2 | selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups | RATIOPHARM GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20080249306-A1 | Method for the Production of Statins | RATIOPHARM GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20070093660-A1 | Method for the production of statins | RATIOPHARM GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093660-A1 | Method for the production of statins | HMGCR, CYP11A1, CYP51A1 | ALDH1A1 673/4885TDP1 3803/4885CYP2C9 78/4885 |
| US-20080249306-A1 | Method for the Production of Statins | HMGCR, COASY, PCSK9 | ALDH1A1 862/4885TDP1 1656/4885CYP2C9 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.